Results 241 to 250 of about 206,973 (317)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Development of an Implementation Strategy Plan to Improve Care for Pediatric Emergency Department Patients With a Possible Sexually Transmitted Infection. [PDF]

Pediatr Emerg Care
Merchant RC, Ramirez-Castillo D, Strother C, Solnick R, Martinez PM, Connell B, Steever J, Clark MA.   +7 more
europepmc   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Incorporating Experiential Learning into Health Information Education: Enhancing Curriculum with Real-World Applications. [PDF]

Adv Health Inf Sci Pract
Houser SH, Flite CA, Foster SL, Kinnerson L, Hunt TJ, Morey A, Pope RD, Sorensen L.   +7 more
europepmc   +1 more source

Classifying RI/FS Costs Under a Policy of Comprehensive General Liability Insurance: Indemnity or Defense [PDF]

, 1994
Eglin, Eileen B, Straus, Stephen D
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Retinal pigment epithelium pathology in age-related macular degeneration: mitigation with melatonin. [PDF]

Front Med (Lausanne)
Reiter RJ, Sharma R, Blasiak J, Rosales-Corral S, Loh D.   +4 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Establishing a Multisectoral Collaborative Drug Diversion Program in a Canadian Health System. [PDF]

Can J Hosp Pharm
Braun N.
europepmc   +1 more source